Vietnam Report Says Need For Bulk Drugs Imports Reflects Hi-Tech Lack
This article was originally published in PharmAsia News
The Drug Administration of Vietnam says local drug production meets only about half of the nation's demand, and even that amount relies mostly on imported bulk drugs. The board chairman of Vietnam Medical Products Import-Export said the cause is a lack of adequate investment in the technologies necessary to exploit medicinal plants. The Vietnamese drug industry lacks the large high-tech extraction plants necessary to end its reliance on bulk imports from China and other countries, the chairman alleged. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.